While I am the first to admit I don't have any judgement when it comes to predicting when a company will raise capital, I just don't get the sense that Imugene will be looking to raise capital at these levels, unless ( and this is a huge unless), they have a big announcement about near future development of one of their treatments towards approval, including along with listing on the US stock exchange.
I agree with several other posters that funds will be required by mid 2025 if not before as running 3 trials simultaneously and maintaining fairly high remuneration for their highly qualified scientists and upper management is not sustainable even when being as frugal as Leslie continues to say she is.
A sale of Hervaxx may tide us over for another year and Leslie has made no secret that of this being their intention, good results of the other B-cell trials may lead this towards a sale as well.
The trifecta of Azer-cel, Vaxinia and OnCARlytics are not ready for sale or licensing out, but as they present more convincing data their value will grow quickly and exponentially, many shareholders I feel hold the greatest hopes on these treatments.
I recall making some ridiculous statement this time last year along the lines of feeling some great news appeared to be imminent, boy that was a inciteful thing to say, and this year feels very much like the can is being continuously kicked down the road, with repetition of old news and expressed hopes of continued exciting data
Time will reveal.
DYOR opinion only
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)